Policy
FDA Proposes Excluding Weight-Loss Drugs From Compounding List
The U.S. Food and Drug Administration (FDA) proposed excluding semaglutide, tirzepatide, and liraglutide—the active ingredients in popular weight-loss drugs like Wegovy, Ozempic, Zepbound, and Mounjaro—from its 503B bulks list. The agency cited the availability of FDA-approved versions of these medi
Apr 30, 5:34 PM ET·2 min read
3 articles from 3 publishers
